Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gram Negative Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Shigella Vaccine and Challenge

NCT04242264
View directory record Official record
Conditions
Immunisation, Shigella Infection
Interventions
Placebo, Shigella sonnei strain 53G, WRSs2
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Decatur, Georgia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01599806
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 2 Interventional Results available

Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

NCT01778634
View directory record Official record
Conditions
Ureaplasma Infections
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
2 Hours to 72 Hours
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Newark, Delaware • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Jul 23, 2026, 12:43 PM EDT
Recruiting Phase 4 Interventional

Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries

NCT07465432
View directory record Official record
Conditions
Drug Clearance After Severe Burn Injury
Interventions
Cefiderocol
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 23, 2026, 12:43 PM EDT
Completed No phase listed Observational

Etiology of Community Acquired Pneumonia

NCT00471757
View directory record Official record
Conditions
Streptococcus Pneumonia, Haemophilus Influencae, Mycoplasma Pneumonia, Chlamydia Pneumonia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Jul 23, 2026, 12:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

NCT06938867
View directory record Official record
Conditions
E Coli Infections, Allogenic Transplant Patients
Interventions
SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL
Biological · Other
Lead sponsor
SNIPR Biome Aps.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 12:43 PM EDT
Completed No phase listed Observational

Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

NCT00573521
View directory record Official record
Conditions
Enterobacteriaceae Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Jul 23, 2026, 12:43 PM EDT
Withdrawn No phase listed Observational

Surveillance Study - Incidence of Antibiotic Resistance in Serial Gram-negative Bloodstream Isolates

NCT00394784
View directory record Official record
Conditions
Gram-negative Bacterial Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 1 Interventional

E. Coli for Prevention of Catheter UTI in SCI Patients

NCT00458471
View directory record Official record
Conditions
Urinary Tract Infection(UTI)
Interventions
Insertion of a urinary catheter coated with benign E. coli
Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2007 · Synced Jul 23, 2026, 12:43 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

NCT01570192
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

NCT00369824
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years · Female only
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Online HIV Prevention for Young Male Couples

NCT03284541
View directory record Official record
Conditions
Hiv, Chlamydia, Gonorrhea
Interventions
2GETHER, Existing Public Health Practice
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jul 23, 2026, 12:43 PM EDT
Recruiting Not applicable Interventional

RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)

NCT07322302
View directory record Official record
Conditions
Trachoma, Eye Diseases, Trichiasis
Interventions
B-RAP, BLTR
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

NCT03965130
View directory record Official record
Conditions
Healthy Participants
Interventions
Glucagon, Control Study
Biological · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

NCT01732627
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections, Invasive Meningococcal Disease
Interventions
Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
56 Years and older
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Scottsdale, Arizona • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Challenge Study of an ETEC Vaccine

NCT01922856
View directory record Official record
Conditions
Enteritis; Escherichia Coli, Enterotoxigenic
Interventions
LTR192G with dscCfaE, No Intervention
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

TY800 Dose Escalation (Typhoid)

NCT00269295
View directory record Official record
Conditions
Typhoid and Paratyphoid Fevers
Interventions
Ty800, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Jul 23, 2026, 12:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Volatile Organic Compounds in Cystic Fibrosis

NCT01379040
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
Cystic Fibrosis patients
Other
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
1 Year to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

NCT00483574
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV), Routine paediatric vaccine - Hepatitis A
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Not applicable Interventional Results available

A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections

NCT06369220
View directory record Official record
Conditions
Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection, Mycoplasma Genitalium Infection
Interventions
cobas® liat CT/NG/MG nucleic acid test, Standard of Care (SOC): Clinician's Standard Practice
Diagnostic Test · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
San Francisco, California • Hamilton Square, New Jersey • Perth Amboy, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 12:43 PM EDT
Recruiting No phase listed Observational

Navigating Pregnancy and Parenthood With Lyme Disease

NCT06397794
View directory record Official record
Conditions
Lyme Disease, Post Treatment Lyme Disease, Chronic Lyme Disease, Tick-Borne Infections, Tick-Borne Diseases, Pregnancy Complications, Parenting
Interventions
Quantitative surveys and qualitative interview
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 3 Interventional Results available

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00112359
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg three times a day (TID), Placebo three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Jul 23, 2026, 12:43 PM EDT
Active, not recruiting Phase 4 Interventional

Kebele Elimination of Trachoma for Ocular Health

NCT03335072
View directory record Official record
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
320,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jul 23, 2026, 12:43 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi

NCT02499172
View directory record Official record
Conditions
Miscarriage, Stillbirth, Cholera
Interventions
Shanchol
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
15 Years to 49 Years · Female only
Enrollment
2,758 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jul 23, 2026, 12:43 PM EDT